Primary Open-Angle Glaucoma (POAG) Guidelines: Guidelines Summary, Preferred practice pattern on primary open-angle glaucoma by the American Academy of Ophthalmology (2025)

  1. Rhee DJ. Glaucoma. Porter RE. The Merck Manual of Diagnosis and Therapy. Rahway, NJ: Merck & Co Inc; Reviewed/Revised April 2023. [Full Text].

  2. Bertaud S, Aragno V, Baudouin C, Labbé A. [Primary open-angle glaucoma]. Rev Med Interne. 2019 Jul. 40 (7):445-452. [QxMD MEDLINE Link].

  3. Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed II, et al. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-up. Ophthalmology. 2022 Dec. 129 (12):1344-1356. [QxMD MEDLINE Link].

  4. Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. J Glaucoma. 1998 Jun. 7(3):165-9. [QxMD MEDLINE Link].

  5. Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992 Apr 15. 113(4):447-52. [QxMD MEDLINE Link].

  6. Krzyzanowska I, Töteberg-Harms M. [Angle-closure glaucoma]. Ophthalmologie. 2022 Nov. 119 (11):1167-1179. [QxMD MEDLINE Link].

  7. Lee CS, Larson EB, Gibbons LE, Lee AY, McCurry SM, Bowen JD, et al. Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease. Alzheimers Dement. 2018 Aug 2. [QxMD MEDLINE Link].

  8. De Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R Jr, et al. Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol. 2011 May. 129(5):562-8. [QxMD MEDLINE Link].

  9. Francis BA, Hong B, Winarko J, et al. Vision loss and recovery after trabeculectomy: risk and associated risk factors. Arch Ophthalmol. 2011 Aug. 129(8):1011-7. [QxMD MEDLINE Link].

  10. Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea. 2008 May. 27(4):488-93. [QxMD MEDLINE Link].

  11. Kass MA, Hart WM Jr, Gordon M, et al. Risk factors favoring the development of glaucomatous visual field loss in ocular hypertension. Surv Ophthalmol. 1980 Nov-Dec. 25(3):155-62. [QxMD MEDLINE Link].

  12. Quigley HA, Enger C, Katz J, et al. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994 May. 112(5):644-9. [QxMD MEDLINE Link].

  13. Rivera JL, Bell NP, Feldman RM. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Curr Opin Ophthalmol. 2008 Mar. 19(2):102-6. [QxMD MEDLINE Link].

  14. Roach L. Narrow retinal vessels raise risk for open-angle glaucoma. Medscape Medical News. January 9, 2013. Medscape. Available at https://www.medscape.com/viewarticle/777428. January 9, 2013; Accessed: October 21, 2024.

  15. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996 Nov. 41 Suppl 1:S39-47. [QxMD MEDLINE Link].

  16. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996 Nov. 41 Suppl 1:S27-37. [QxMD MEDLINE Link].

  17. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May. 45 Suppl 4:S347-51. [QxMD MEDLINE Link].

  18. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May. 45 Suppl 4:S337-45. [QxMD MEDLINE Link].

  19. Lin SC. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma. 2008 Apr-May. 17(3):238-47. [QxMD MEDLINE Link].

  20. Lin SC. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma. 2008 Apr-May. 17(3):238-47. [QxMD MEDLINE Link].

  21. Yu JY, Kahook MY, Lathrop KL, et al. The effect of probe placement and type of viscoelastic material on endoscopic cyclophotocoagulation laser energy transmission. Ophthalmic Surg Lasers Imaging. 2008 Mar-Apr. 39(2):133-6. [QxMD MEDLINE Link].

  22. Sunaric-Megevand G, Leuenberger PM. Results of viscocanalostomy for primary open-angle glaucoma. Am J Ophthalmol. 2001 Aug. 132(2):221-8. [QxMD MEDLINE Link].

  23. [Guideline] Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2021 Jan. 128 (1):P71-P150. [QxMD MEDLINE Link]. [Full Text].

  24. Costa VP, Jimenez-Roman J, Carrasco FG, Lupinacci A, Harris A. Twenty-four-hour ocular perfusion pressure in primary open-angle glaucoma. Br J Ophthalmol. 2010 Oct. 94(10):1291-4. [QxMD MEDLINE Link].

  25. Leske MC, Connell AM, Wu SY, et al. Distribution of intraocular pressure. The Barbados Eye Study. Arch Ophthalmol. 1997 Aug. 115(8):1051-7. [QxMD MEDLINE Link].

  26. Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, De Jong PT, Vingerling JR, et al. Incidence of Glaucomatous Visual Field Loss: A Ten-Year Follow-up from the Rotterdam Study. Ophthalmology. 2010 Sep. 117(9):1705-12. [QxMD MEDLINE Link].

  27. Yadav M, Bhardwaj A, Yadav A, Dada R, Tanwar M. Molecular genetics of primary open-angle glaucoma. Indian J Ophthalmol. 2023 May. 71 (5):1739-1756. [QxMD MEDLINE Link].

  28. Brandt JD, Beiser JA, Gordon MO, et al. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004 Nov. 138(5):717-22. [QxMD MEDLINE Link].

  29. Brandt JD, Beiser JA, Kass MA, et al. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001 Oct. 108(10):1779-88. [QxMD MEDLINE Link].

  30. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun. 120(6):714-20; discussion 829-30. [QxMD MEDLINE Link].

  31. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999 May. 117(5):573-83. [QxMD MEDLINE Link].

  32. Shih CY, Graff Zivin JS, Trokel SL, et al. Clinical significance of central corneal thickness in the management of glaucoma. Arch Ophthalmol. 2004 Sep. 122(9):1270-5. [QxMD MEDLINE Link].

  33. McNamara D. Predictors of Rapid Glaucoma Progression Identified. Medscape Medical News. Available at https://www.medscape.com/viewarticle/805049. May 30, 2013; Accessed: October 21, 2024.

  34. Brusini P, Salvetat ML, Zeppieri M, et al. Comparison of ICare tonometer with Goldmann applanation tonometer in glaucoma patients. J Glaucoma. 2006 Jun. 15(3):213-7. [QxMD MEDLINE Link].

  35. Racette L, Sample PA. Short-wavelength automated perimetry. Ophthalmol Clin North Am. 2003 Jun. 16(2):227-36, vi-vii. [QxMD MEDLINE Link].

  36. Reus NJ, Colen TP, Lemij HG. The prevalence of glaucomatous defects with short-wavelength automated perimetry in patients with elevated intraocular pressures. J Glaucoma. 2005 Feb. 14(1):26-9. [QxMD MEDLINE Link].

  37. Bengtsson B. A new rapid threshold algorithm for short-wavelength automated perimetry. Invest Ophthalmol Vis Sci. 2003 Mar. 44(3):1388-94. [QxMD MEDLINE Link].

  38. Bengtsson B, Heijl A. Normal intersubject threshold variability and normal limits of the SITA SWAP and full threshold SWAP perimetric programs. Invest Ophthalmol Vis Sci. 2003 Nov. 44(11):5029-34. [QxMD MEDLINE Link].

  39. Tezel G, Kolker AE, Kass MA, et al. Parapapillary chorioretinal atrophy in patients with ocular hypertension. I. An evaluation as a predictive factor for the development of glaucomatous damage. Arch Ophthalmol. 1997 Dec. 115(12):1503-8. [QxMD MEDLINE Link].

  40. Tezel G, Kolker AE, Wax MB, et al. Parapapillary chorioretinal atrophy in patients with ocular hypertension. II. An evaluation of progressive changes. Arch Ophthalmol. 1997 Dec. 115(12):1509-14. [QxMD MEDLINE Link].

  41. Rao HL, Kumar AU, Babu JG, Senthil S, Garudadri CS. Relationship between Severity of Visual Field Loss at Presentation and Rate of Visual Field Progression in Glaucoma. Ophthalmology. 2011 Feb. 118(2):249-53. [QxMD MEDLINE Link].

  42. Nouri-Mahdavi K, Zarei R, Caprioli J. Influence of visual field testing frequency on detection of glaucoma progression with trend analyses. Arch Ophthalmol. 2011 Dec. 129(12):1521-7. [QxMD MEDLINE Link].

  43. Traynis I, De Moraes CG, Raza AS, Liebmann JM, Ritch R, Hood DC. Prevalence and nature of early glaucomatous defects in the central 10° of the visual field. JAMA Ophthalmol. 2014 Jan 9. [QxMD MEDLINE Link].

  44. Laidman J. Early glaucoma damage sometimes missed by visual field test. Medscape Medical News. January 17, 2014. [Full Text].

  45. Poli A, Strouthidis NG, Ho TA, et al. Analysis of HRT images: comparison of reference planes. Invest Ophthalmol Vis Sci. 2008 Sep. 49(9):3970-5. [QxMD MEDLINE Link].

  46. Medeiros FA, Zangwill LM, Bowd C, et al. Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma. Arch Ophthalmol. 2004 Jun. 122(6):827-37. [QxMD MEDLINE Link].

  47. Nouri-Mahdavi K, Nikkhou K, Hoffman DC, et al. Detection of early glaucoma with optical coherence tomography (StratusOCT). J Glaucoma. 2008 Apr-May. 17(3):183-8. [QxMD MEDLINE Link].

  48. Leung CK, Yu M, Weinreb RN, Lai G, Xu G, Lam DS. Retinal Nerve Fiber Layer Imaging with Spectral-domain Optical Coherence Tomography: Patterns of Retinal Nerve Fiber Layer Progression. Ophthalmology. 2012 Jun 5. [QxMD MEDLINE Link].

  49. Leung CK, Liu S, Weinreb RN, et al. Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression. Ophthalmology. 2011 Aug. 118(8):1551-7. [QxMD MEDLINE Link].

  50. Medeiros FA, Zangwill LM, Anderson DR, Liebmann JM, Girkin CA, Harwerth RS, et al. Estimating the Rate of Retinal Ganglion Cell Loss in Glaucoma. Am J Ophthalmol. 2012 Jul 26. [QxMD MEDLINE Link].

  51. Chihara E. Assessment of true intraocular pressure: the gap between theory and practical data. Surv Ophthalmol. 2008 May-Jun. 53(3):203-18. [QxMD MEDLINE Link].

  52. ElMallah MK, Asrani SG. New ways to measure intraocular pressure. Curr Opin Ophthalmol. 2008 Mar. 19(2):122-6. [QxMD MEDLINE Link].

  53. Annette H, Kristina L, Bernd S, Mark-Oliver F, Wolfgang W. Effect of central corneal thickness and corneal hysteresis on tonometry as measured by dynamic contour tonometry, ocular response analyzer, and Goldmann tonometry in glaucomatous eyes. J Glaucoma. 2008 Aug. 17(5):361-5. [QxMD MEDLINE Link].

  54. Kaufmann C, Bachmann LM, Thiel MA. Comparison of dynamic contour tonometry with goldmann applanation tonometry. Invest Ophthalmol Vis Sci. 2004 Sep. 45(9):3118-21. [QxMD MEDLINE Link].

  55. Reichert, Inc. The Ocular Response Analyzer. Reichert, Inc. Available at https://www.reichert.com/en/products/ocular-response-analyzer-g3. Accessed: October 21, 2024.

  56. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacol Biochem Behav. 2008 May 25. [QxMD MEDLINE Link].

  57. Chen TC, Ahn Yuen SJ, Sangalang MA, Fernando RE, Leuenberger EU. Retrobulbar chlorpromazine injections for the management of blind and seeing painful eyes. J Glaucoma. 2002 Jun. 11(3):209-13. [QxMD MEDLINE Link].

  58. Van Buskirk EM. Medicolegal aspects of glaucoma care. Surv Ophthalmol. 1998 Jul-Aug. 43(1):83-6. [QxMD MEDLINE Link].

  59. Heijl A, Peters D, Leske MC, Bengtsson B. Effects of argon laser trabeculoplasty in the early manifest glaucoma trial. Am J Ophthalmol. 2011 Nov. 152(5):842-8. [QxMD MEDLINE Link].

  60. Allen RC, Netland PA, eds. Glaucoma Medical Therapy: Principles and Management. American Academy of Ophthalmology; 1999.

  61. Rocklatan (netarsudil and latanoprost ophthalmic solution) [package insert]. Irvine, CA: Aerie Pharmaceuticals. March, 2019. Available at [Full Text].

  62. Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci. 2008 Jun. 85(6):406-16. [QxMD MEDLINE Link].

  63. Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, et al. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2017 Nov 30. [QxMD MEDLINE Link].

  64. Minckler DS. Histology of optic nerve damage in ocular hypertension and early glaucoma. Surv Ophthalmol. 1989 Apr. 33 Suppl:401-2; discussion 409-11. [QxMD MEDLINE Link].

  65. Cantor L. Section 10: Glaucoma. Basic and Clinical Science Course. American Academy of Ophthalmology; 1996-1997.

  66. Ritch, Shields, Krupin, eds. The Glaucomas. 2nd ed. 1992.

  67. Shields MB. Textbook of Glaucoma. 4th ed. Lippincott Williams & Wilkins; 1998.

  68. Spaeth GL. Early primary open-angle glaucoma: diagnosis and management. Preface. Int Ophthalmol Clin. 1979 Spring. 19(1):vii-ix. [QxMD MEDLINE Link].

  69. Stamper RL, Lieberman MF, Drake MV. Becker-Shaffers Diagnosis and Therapy of the Glaucomas. 7th ed. Mosby-Year Book; 1999.

Primary Open-Angle Glaucoma (POAG) Guidelines: Guidelines Summary, Preferred practice pattern on primary open-angle glaucoma by the American Academy of Ophthalmology (2025)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Arline Emard IV

Last Updated:

Views: 6486

Rating: 4.1 / 5 (52 voted)

Reviews: 91% of readers found this page helpful

Author information

Name: Arline Emard IV

Birthday: 1996-07-10

Address: 8912 Hintz Shore, West Louie, AZ 69363-0747

Phone: +13454700762376

Job: Administration Technician

Hobby: Paintball, Horseback riding, Cycling, Running, Macrame, Playing musical instruments, Soapmaking

Introduction: My name is Arline Emard IV, I am a cheerful, gorgeous, colorful, joyous, excited, super, inquisitive person who loves writing and wants to share my knowledge and understanding with you.